randomized controlled trials

You have accessRestricted Access
Optimizing the Design and Analysis of Future AKI Trials
Matthieu Legrand, Sean M. Bagshaw, Jay L. Koyner, Ivonne H. Schulman, Michael R. Mathis, Juliane Bernholz, Steven Coca, Martin Gallagher, Stéphane Gaudry, Kathleen D. Liu, Ravindra L. Mehta, Romain Pirracchio, Abigail Ryan, Dominik Steubl, Norman Stockbridge, Fredrik Erlandsson, Alparslan Turan, F. Perry Wilson, Alexander Zarbock, Michael P. Bokoch, Jonathan D. Casey, Patrick Rossignol and Michael O. Harhay

JASN August 2022, 33 (8) 1459-1470; DOI: https://doi.org/10.1681/ASN.2021121605

Add to Selected Citations
You have accessRestricted Access
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
Michele Provenzano, Maria Jesús Puchades, Carlo Garofalo, Niels Jongs, Luis D’Marco, Michele Andreucci, Luca De Nicola, Jose Luis Gorriz and Hiddo J.L. Heerspink; on behalf of the ROTATE-3 study group

JASN August 2022, 33 (8) 1569-1580; DOI: https://doi.org/10.1681/ASN.2022020207

Add to Selected Citations
You have accessRestricted Access
More Research is Still Needed To Support The Real-world Generalizability of The Benefits of Lifestyle Interventions for CKD
Liuyan Huang and Fan Zhang

JASN May 2022, 33 (5) 1045; DOI: https://doi.org/10.1681/ASN.2022020172

Add to Selected Citations
You have accessRestricted Access
Authors’ Reply: More Research is Still Needed to Support the Real-World Generalizability of the Benefits of Lifestyle Interventions for Chronic Kidney Disease
Kassia S. Beetham, Jeff S. Coombes and Erin J. Howden

JASN May 2022, 33 (5) 1045-1046; DOI: https://doi.org/10.1681/ASN.2022030244

Add to Selected Citations
You have accessRestricted Access
Plasma Exchange in ANCA-Associated Vasculitis: For Whom (If Any)?
Michael Walsh

JASN March 2022, 33 (3) 465-466; DOI: https://doi.org/10.1681/ASN.2021121550

Add to Selected Citations
You have accessRestricted Access
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Brendon L. Neuen, Hocine Tighiouart, Hiddo J.L. Heerspink, Edward F. Vonesh, Juhi Chaudhari, Shiyuan Miao, Tak Mao Chan, Fernando C. Fervenza, Jürgen Floege, Marian Goicoechea, William G. Herrington, Enyu Imai, Tazeen H. Jafar, Julia B. Lewis, Philip Kam-Tao Li, Francesco Locatelli, Bart D. Maes, Ronald D. Perrone, Manuel Praga, Annalisa Perna, Francesco P. Schena, Christoph Wanner, Jack F.M. Wetzels, Mark Woodward, Di Xie, Tom Greene, Lesley A. Inker and on behalf of CKD-EPI Clinical Trials

JASN February 2022, 33 (2) 291-303; DOI: https://doi.org/10.1681/ASN.2021070948

Add to Selected Citations
Open Access
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
Rajiv Agarwal, Amer Joseph, Stefan D. Anker, Gerasimos Filippatos, Peter Rossing, Luis M. Ruilope, Bertram Pitt, Peter Kolkhof, Charlie Scott, Robert Lawatscheck, Daniel J. Wilson, George L. Bakris and on behalf of the FIDELIO-DKD Investigators

JASN January 2022, 33 (1) 225-237; DOI: https://doi.org/10.1681/ASN.2021070942

Add to Selected Citations
You have accessRestricted Access
Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial
Jeffrey A. Sparks, Kathleen M. M. Vanni, Matthew A. Sparks, Chang Xu, Leah M. Santacroce, Robert J. Glynn, Paul M. Ridker and Daniel H. Solomon

JASN December 2021, 32 (12) 3197-3207; DOI: https://doi.org/10.1681/ASN.2021050598

Add to Selected Citations
Open Access
Conversion from Calcineurin Inhibitor– to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial
Klemens Budde, Rohini Prashar, Hermann Haller, Maria C. Rial, Nassim Kamar, Avinash Agarwal, Johan W. de Fijter, Lionel Rostaing, Stefan P. Berger, Arjang Djamali, Nicolae Leca, Lisa Allamassey, Sheng Gao, Martin Polinsky and Flavio Vincenti

JASN December 2021, 32 (12) 3252-3264; DOI: https://doi.org/10.1681/ASN.2021050628

Add to Selected Citations
Open Access
Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy: A Post Hoc Analysis from the SONAR Trial
Simke W. Waijer, Sieta T. de Vries, Robert Busch, Di Xie, Ron T. Gansevoort, Fan Fan Hou, Jose L. Górriz, Gozewijn D. Laverman, Luca De Nicola, Julio Pascual, Michele Provenzano, Pablo E. Pergola, Sydney C.W. Tang, Christoph Wanner, Philippe Zaoui, Hans-Henrik Parving, Dick de Zeeuw and Hiddo J.L. Heerspink

JASN November 2021, 32 (11) 2731-2734; DOI: https://doi.org/10.1681/ASN.2021040498

Add to Selected Citations

Main menu

User menu

Search

randomized controlled trials

Pages

Articles

Information for Authors

About

Journal Information

More Information